Revisions
To ensure that we are providing our clients with the industry’s best and most current clinical information, we complete a 'post-publication' process and receive feedback regarding opportunities to add additional information or, in rare cases, make revisions.
Below is information on revisions, corrections, or modifications to existing monographs that have been identified in the past 12 months.
Cholecalciferol - August 2010
Revision in the Dosage Forms field of the Cholecalciferol monograph in Lexi-Drugs online and handheld offerings.
The monograph previously read:
Dosage Forms
Solution, oral:
- Bio-D-Mulsion Forte® [OTC]: 2000 int. units/mL (30 mL)
- Bio-D-Mulsion® [OTC]: 400 int. units/mL (30 mL)
- DDrops® [OTC]: 2000 int. units/mL (10 mL); 1000 units/mL (10 mL)
- DDrops® Baby [OTC]: 400 int. units/mL (10 mL)
- DDrops® Kids [OTC]: 400 int. units/mL (10 mL)
- Enfamil® D-Vi-Sol? [OTC]: 400 int. units/mL (150 mL)
It has been revised to read:
Solution, oral:
- Bio-D-Mulsion Forte®: 2000 int. units/mLdrop (30 mL)
- Bio-D-Mulsion®: 400 int. units/mLdrop(30 mL)
- DDrops®: 2000 int. units/mLdrop (10 mL); 1000 units/mLdrop (10 mL)
- DDrops® Baby: 400 int. units/mLdrop (10 mL)
- DDrops® Kids: 400 int. units/mLdrop (10 mL)
- Enfamil® D-Vi-Sol?: 400 int. units/mL (150 mL)
These changes have been automatically posted to online and hand-held reference sources.
Ketamine - March 2010
Revision in the Dosage field of the Ketamine monograph in Lexi-Drugs, the Drug Information Handbook, 19th edition, domestic version, and the Anesthesiology and Critical Care Drug Handbook, 9th edition
The monograph previously read (only portion of field impacted is presented):
Dosing: Adult
Maintenance of anesthesia: Supplemental doses of 1/2 to the full induction dose; may also be maintained with a continuous infusion of 0.1-5 mg/minute
It has been corrected to read (only portion of field impacted is presented):
Dosing: Adult
Maintenance of anesthesia: Supplemental doses of 1/2 to the full induction dose; may also be maintained with a continuous infusion of 0.1-0.5 mg/minute
These changes have been automatically posted to online and hand-held reference sources, but the previous information will persist in the current print edition.
Digoxin - March 2010
Revision in the Dosage field of the Digoxin monograph in Lexi-Drugs and the Drug Information Handbook, 19th edition.
The monograph previously read (only portion of field impacted is presented):
Dosage: Adult:
Supraventricular tachyarrhythmias (rate control):
- Initial: Total digitalizing dose:
- Oral: 0.75-1.5 mg
- I.V., I.M.: 0.5-1 mg (Note: I.M. not preferred due to severe injection site pain.)
- Give 1/2 of the total digitalizing dose (TDD) as the initial dose, then give 1/2 of the TDD in each of 2 subsequent doses at 6- to 8-hour intervals. Obtain ECG 6 hours after each dose to assess potential toxicity.
It has been corrected to read (only portion of field impacted is presented):
Dosage: Adult:
Supraventricular tachyarrhythmias (rate control):
- Initial: Total digitalizing dose:
- Oral: 0.75-1.5 mg
- I.V., I.M.: 0.5-1 mg (Note: I.M. not preferred due to severe injection site pain.)
- Give 1/2 (one-half) of the total digitalizing dose (TDD) as the initial dose, then give 1/4 (one-quarter) of the TDD in each of 2 subsequent doses at 6- to 8-hour intervals. Obtain ECG 6 hours after each dose to assess potential toxicity.
These changes have been automatically posted to online and hand-held reference sources, but the previous information will persist in the current print edition.
Aldesleukin - December 2009
Revision in the Dosage (Usual) field of the Aldesleukin monograph in Pediatric Lexi-Drugs and the Pediatric Dosage Handbook, 16th edition.
The monograph previously read:
Dosage (Usual): (only portion of field impacted is presented)
AML: Children: (Investigational use only, Sievers, 1998): Continuous I.V. infusion: 9 million international units (9 x 106 international units) daily for 4 days; repeat 4 days later with 1.6 million international units (1.6 x 106 international units) daily for 10 days
It has been corrected to read:
Dosage (Usual): (only portion of field impacted is presented)
AML: Children: (Investigational use only, Sievers, 1998): Continuous I.V. infusion: 9 million international units/m2 (9 x 106 international units//m2) daily for 4 days; repeat 4 days later with 1.6 million international units//m2 (1.6 x 106 international units//m2 daily for 10 days
These changes have been automatically posted to online and hand-held reference sources, but the previous information will persist in the current print edition.
Hydromorphone - November 2009
Revision in the Dosing: Adults field of the Hydromorphone monograph in Lexi-Drugs online and handheld offerings.
The monograph previously read:
Dosing: Adults
- Oral:
- Initial: Opiate-naive: 2-4 mg every 3-6 hours as needed; elderly/debilitated patients may require lower doses; patients with prior opiate exposure may require higher initial doses
- Usual dosage range: 2-8 mg every 3-4 hours as needed
- I.V.: Initial: Opiate-naive: 0.2-0.6 mg every 2-3 hours as needed; patients with prior opiate exposure may tolerate higher initial doses. Note: The American Pain Society recommends an initial dose of 4-8 mg for severe pain in adults.
- Critically-ill patients (unlabeled dose): 0.7-2 mg (based on 70 kg patient) every 1-2 hours as needed. Note: More frequent dosing may be needed (eg, mechanically-ventilated patients).
- Continuous infusion: Usual dosage range: 0.5-1 mg/hour (based on 70 kg patient) or 7-15 mcg/kg/hour
It has been corrected to read:
Dosing: Adults
- Oral:
- Initial: Opiate-naive: 2-4 mg every 3-6 hours as needed; elderly/debilitated patients may require lower doses; patients with prior opiate exposure may require higher initial doses
- Usual dosage range: 2-8 mg every 3-4 hours as needed
- Note: The American Pain Society recommends an initial dose of 4-8 mg for severe pain in adults.
- I.V.: Initial: Opiate-naive: 0.2-0.6 mg every 2-3 hours as needed; patients with prior opiate exposure may tolerate higher initial doses. Note: The American Pain Society recommends an initial dose of 4-8 mg for severe pain in adults.
- Critically-ill patients (unlabeled dose): 0.7-2 mg (based on 70 kg patient) every 1-2 hours as needed. Note: More frequent dosing may be needed (eg, mechanically-ventilated patients).
- Continuous infusion: Usual dosage range: 0.5-1 mg/hour (based on 70 kg patient) or 7-15 mcg/kg/hour
These changes have been automatically posted to online and hand-held reference sources.
Rifabutin - May 2009
Revision in the Contraindications field of the Rifabutin monograph in Lexi-Drugs, Drug Information Handbook, 18th edition (both domestic and international editions), Drug Information Handbook for Dentistry, 14th edition, Drug Information Handbook for Nursing, 11th edition, and Drug Information Handbook for Advanced Practice Nursing, 10th edition.
The monograph previously read:
Contraindications
Hypersensitivity to rifabutin, any other rifamycins, or any component of the formulation; rifabutin is contraindicated in patients with a WBC <1000/mm3 or a platelet count <50,000 mm3
It has been corrected to read:
Contraindications
Hypersensitivity to rifabutin, any other rifamycins, or any component of the formulation
These changes have been automatically posted to online and hand-held reference sources, but the previous information will persist in the current print editions.
Nitrofurantoin - May 2009
Revision in the Drug of Choice or Alternative for Disease/Syndrome(s) field of the Nitrofurantoin monograph in Lexi-Drugs and Infectious Diseases databases.
The monograph previously read:
Drug of Choice or Alternative for Disease/Syndrome(s)
- Asymptomatic Bacteriuria
- Pyelonephritis
- Urinary Tract Infection, Uncomplicated
It has been corrected to read:
Drug of Choice or Alternative for Disease/Syndrome(s)
- Asymptomatic Bacteriuria
- Urinary Tract Infection, Uncomplicated
Pyelonephritis has been removed from the listing. These changes have been automatically posted to online and hand-held reference sources.
Ranitidine - May 2009
Revision in the Dosage field of the Ranitidine monograph in Lexi-Drugs, Pediatric Lexi-Drugs, Drug Information Handbook, 18th edition (both domestic and international editions), Pediatric Dosage Handbook, 15th edition, Drug Information Handbook for Dentistry, 14th edition, Drug Information Handbook for Nursing, 11th edition, Drug Information Handbook for Advanced Practice Nursing, 10th edition, and Anesthesiology and Critical Care Drug Handbook, 8th edition.
The monograph previously read:
Dosage
Children ≥1 month to 16 years:
Gastric/duodenal ulcer:
Oral:
Treatment: 2-4 mg/kg/day divided twice daily; maximum: 300 mg/day
Maintenance: 2-4 mg/kg/day once daily; maximum: 150 mg/day
It has been corrected to read:
Dosage
Children ≥1 month to 16 years:
Gastric/duodenal ulcer:
Oral:
Treatment: 4-8 mg/kg/day divided twice daily; maximum: 300 mg/day
Maintenance: 2-4 mg/kg/day once daily; maximum: 150 mg/day [Pediatric database only]
These changes have been automatically posted to online and hand-held reference sources, but the previous information will persist in the current print editions.
Famciclovir - April 2009
Revision in the Dosage field of the Famciclovir monograph in Lexi-Drugs, Pediatric Lexi-Drugs, Geriatric Lexi-Drugs, Dental Lexi-Drugs, Drug Information Handbook, 18th edition, Pediatric Dosage Handbook, 15th edition, Geriatric Dosage Handbook, 14th edition, Drug Information Handbook for Dentistry, 14th edition, Drug Information Handbook for Nursing, 10th edition, Drug Information Handbook for Advanced Practice Nursing, 9th edition, and Drug Information Handbook for Oncology, 7th edition.
The monograph previously read:
Dosage: (only portion of Dosage field affected shown)
Dosing interval in renal impairment:
Recurrent orolabial or genital herpes in HIV-infected patients:
Clcr 20-39 mL/minute: Administer 500 mg every 12 hours
Clcr <20 mL/minute: Administer 250 mg every 24 hours
Hemodialysis: Administer 250 mg after each dialysis session.
It has been corrected to read:
Dosage: (only portion of Dosage field affected shown)
Dosing interval in renal impairment:
Recurrent orolabial or genital herpes in HIV-infected patients:
Clcr 20-39 mL/minute: Administer 500 mg every 24 hours
Clcr <20 mL/minute: Administer 250 mg every 24 hours
Hemodialysis: Administer 250 mg after each dialysis session.
These changes have been automatically posted to online and hand-held reference sources, but the previous information will persist in the current print editions.
